R.I. SADYKOV, I.F. AKHTYAMOV, G.M. FAIZRAKHMANOVA

 Kazan State Medical University, Kazan

 Contact details:

Sadykov R.I. — Assistant Lecturer of the Department of Traumatology, Orthopedics and Surgery of Extreme States

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.:+7-917-253-61-46, e-mail: rustiksadykov@mail.ru

Despite advances in traumatology and orthopedics, the problem of fracture treatment remains topical. To normalize the timing of fracture healing, both drug treatment and local factors of reparative osteogenesis stimulation are used.

The purpose — to study the effect of the combined use of an ossein-hydroxyapatite complex and bisphosphonates on the timing of fracture consolidation and on the bone mineral density.

Material and methods. In 20 patients aged 50 to 75 years with closed fractures of the femoral diaphysis after intramedullary metal osteosynthesis, the timing of fracture healing and the changes in bone mineral density were assessed one year after the fracture in two equal in number and comparable groups. In the comparison group, patients received ossein-hydroxyapatite complex and сolecalciferol; in the main group, patients received ossein-hydroxyapatite complex, сolecalciferol, and 1 month after the operation, they received a single intravenous injection of zoledronic acid. The RUST scale was used to assess the signs of fracture union by radiographs. Complete union of the fracture was recorded with a total of 10 or more points. Osteodensitometry was performed in patients twice, after surgery and one year after it.

Results. With the combined use of the ossein-hydroxyapatite complex and bisphosphonates in patients in the study group, the timing of fracture healing was 2.1 weeks less than in the comparison group, and the increase in bone mineral density in the lumbar spine was by 1.8% larger, in the femoral neck by 1.4% larger in the main group than in the comparison group. Although according to clinical studies, the systemic use of bisphosphonates did not affect the timing of fracture healing, with the combined use of ossein-hydroxyapatite complex and zoledronic acid, there was a greater increase in bone mineral density and a decrease in the timing of union of a femoral fracture after intramedullary metal osteosynthesis than when using only ossein-hydroxyapatite complex.

Conclusions. A positive effect of the combined use of the ossein-hydroxyapatite complex and bisphosphonates in patients on the timing of fracture healing and bone mineral density was revealed, which is the basis for further research on the use of these drugs in a larger number of patients.

Key words: delayed consolidation of fractures, bisphosphonates, ossein-hydroxyapatite complex.

REFERENCES

1. Injuries, orthopedic morbidity, organization of trauma and orthopedic care in the Russian Federation in 2019: collection. FGBU TsITO im. N.N. Priorova, 2021, pp. 269–275 (in Russ.).
2. Alekseenko S.N., Red’ko A.N., Karipidi R.K., Zakharchenko Yu.I. Primary disability of the adult population of the Krasnodar Territory due to traffic accidents. Vestnik Vserossiyskogo obshchestva spetsialistov po mediko-sotsial’noy ekspertize, reabilitatsii i reabilitatsionnoy industrii, 2017, no. 4, pp. 44–48 (in Russ.).
3. Shalygina O.I., Kuznetsova N.L., Zolotushkin M.L. A new approach to the treatment of patients with delayed fracture consolidation. Geniy ortopedii, 2012, no. 2, pp. 60–62 (in Russ.).
4. Sadykov R.I., Akhtyamov I.F. Modern trends in drug prevention and treatment of patients with delayed fracture consolidation: a review of the literature. Opinion Leader, 2020, no. 7 (36), pp. 34–39 (in Russ.).
5. Aspenberg P. Drugs and fracture repair. Acta Orthopaedica, 2005, vol. 76, pp. 241–248.
6. Camil Castelo-Branco, Manel Ciria-Recasens, María J Cancelo-Hidalgo et al. Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause, 2009, vol. 16 (5), pp. 984–991.
7. Castelo-Branco C., Cancelo Hidalgo M.J., Palacios S. et al. Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric, 2020, vol. 23 (3), pp. 252–258.
8. Orwoll E., Ettinger M., Weiss S. et al. Alendronate for the treatment of osteoporosis in men. The New England Journal of Medicine, 2000, vol. 343 (9), pp. 604–610.
9. Toroptsova N.V., Dobrovol’skaya O.V., Nikitinskaya O.A. Treatment of osteoporosis in clinical practice: focus on bisphosphonates. Effektivnaya farmakoterapiya, 2016, no. 17, pp. 6–10 (in Russ.).
10. Anna Kajsa Harding, Annette W-Dahl, Mats Geijer et al. A single bisphosphonate infusion does not accelerate fracture healing in high tibial osteotomies. Acta Orthopaedica, 2011, vol. 82 (4), pp. 465–470.
11. Yongquan Gao, Xiaochen Liu, Yuan Gu et al. The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis. Frontiers in Endocrinology, 2021, vol. 12, pp. 1–10.
12. Kim T.Y., Ha Y.C., Kang B.J. et al. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J. Bone Joint Surg. Br, 2012, vol. 94 (7), pp. 956–960.
13. Uchiyama S., Itsubo T., Nakamura K. et al. Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. Bone Joint J, 2013, vol. 95 (11), pp. 1544–1550.
14. Leow J.M., Clement N.D., Tawonsawatruk T. et al. The radiographic union scale in tibial (RUST) fractures. J. Bone Joint Research, 2016, vol. 5 (4), pp. 16–121.
15. Patologicheskie perelomy, oslozhnyayushchie osteoporoz. Klinicheskie rekomendatsii [Pathological fractures complicating osteoporosis. Clinical guidelines], 2018. ID: KR614. Pp. 18–35.
16. Rodionova S.S., Torgashin A.N. Pharmacotherapy as a component of the treatment of low-energy fractures of the proximal femur against the background of osteoporosis. Opinion Leader, 2017, no. 3, pp. 30–35 (in Russ.).
17. Hallan G., Lie S.A., Havelin L.I. High wear rates and extensive osteolysis in 3 types of uncemented total hip arthroplasty: a review of the PCA, the Harris Galante and the Profile/Tri-Lock Plus arthroplasties with a minimum of 12 years median follow-up in 96 hips. Acta Orthopaedica, 2006, vol. 77 (4), pp. 575–584.
18. Harding A.K., Toksvig-Larsen S., Tägil M., W-Dahl A. A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients. Bone, 2010, vol. 46 (3), pp. 649–654.
19. Nishioka T., Yagi S., Mitsuhashi T. et al. Alendronate inhibits periprosthetic bone loss around uncemented femoral components. J. Bone Miner. Metab, 2007, vol. 25 (3), pp. 179–183.
20. Harris S., Blumentals W., Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion, 2007, vol. 24 (1), pp. 237–245.
21. Colón-Emeric C., Nordsletten L., Olson S. et al. HORIZON Recurrent Fracture Trial Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int, 2011, vol. 22 (8), pp. 2329–2336.
22. Akhtyamov I.F., Shakirova F.V., Korobeynikova D.A. et al. Influence of components based on lanthanide and calcium ions on bone density in femur fractures in animals. Travmatologiya i ortopediya Rossii, 2020, vol. 26, no. 1, pp. 138–146 (in Russ.).
23. Tsyplakov D.E., Shakirova F.V., Akhtyamov I.F. et al. Somparative morphometric analysis of healing bone fractures under the influence of the preparation based on etidronate without lanthanoid ions and in conjuction with them. Bio Nano Science, 2020, vol. 10 (4), pp. 1143–1151.
24. Dennis M. Black, Ian R. Reid, Steven Boonen et al. The Effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J. Bone Miner. Res, 2012, vol. 27 (2), pp. 243–254.
25. McClung M., Miller P., Recknor C., et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstetrics & Gynecology, 2009, vol. 114 (5), pp. 999–1007.
26. Reid I.R., Horne A.M., Mihov B. et al. Fracture prevention with zoledronate in older women with osteopenia. N. Engl. J. Med, 2018, vol. 379 (25), pp. 2407–2416.